Purpose <p>Acute kidney injury (AKI) is a common complication and a strong risk factor for adverse outcomes after transcatheter aortic valve implantation (TAVI). Renal regional tissue oxygen saturation (rSO<sub>2</sub>) reflects tissue perfusion and can be measured using near-infrared spectroscopy. We hypothesized that decrease in renal rSO<sub>2</sub> during TAVI would predict post-procedural AKI.</p> Methods <p>Patients with severe aortic stenosis who scheduled for transfemoral TAVI were enrolled. Patients undergoing emergent procedures, those with severe renal impairment, those with a distance from skin to renal capsule &gt; 4&#xa0;cm, those on mechanical ventilation, or those who refused to participate were excluded. The primary outcome was the relationship between changes in renal rSO<sub>2</sub> during TAVI and post-procedural AKI. AKI was determined according to the Valve Academic Research Consortium-2 criteria.</p> Results <p>Sixty-four patients were included and analyzed. The mean (standard deviation [SD]) age of patients was 82 (4) years, and the median [interquartile range] procedure time was 75 [65–90] min. The incidence of post-procedural AKI was 33% (21/64). There was no difference in the mean (SD) time-weighted renal rSO<sub>2</sub> (70% [13%] and 73% [11%]), changes in renal rSO<sub>2</sub> (–14% [10%] and − 15% [13%]), or nadir rSO<sub>2</sub> (55% [17%] and 60% [17%]) during TAVI between patients who developed post-TAVI AKI and those who did not (<i>p</i> = 0.227, 0.157, and 0.333, respectively). In multivariable regression analysis, renal rSO<sub>2</sub> variables were not predictors of post-TAVI AKI.</p> Conclusion <p>Procedural changes in renal rSO<sub>2</sub> measured using near-infrared spectroscopy did not predict the development of post-TAVI AKI. Further studies are needed to investigate more effective strategies to predict and prevent AKI following TAVI.</p> Trial registration <p>This study was registered on cinicaltrials.gov (identifier, NCT04921475, registered on June 10, 2021).</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Association of renal regional tissue oxygen saturation and post-procedural acute kidney injury following transcatheter aortic valve implantation

  • Hoo Seung Lee,
  • Youn Joung Cho,
  • Seungho Yoo,
  • Seohee Lee,
  • Jae-Woo Ju,
  • Karam Nam,
  • Yunseok Jeon

摘要

Purpose

Acute kidney injury (AKI) is a common complication and a strong risk factor for adverse outcomes after transcatheter aortic valve implantation (TAVI). Renal regional tissue oxygen saturation (rSO2) reflects tissue perfusion and can be measured using near-infrared spectroscopy. We hypothesized that decrease in renal rSO2 during TAVI would predict post-procedural AKI.

Methods

Patients with severe aortic stenosis who scheduled for transfemoral TAVI were enrolled. Patients undergoing emergent procedures, those with severe renal impairment, those with a distance from skin to renal capsule > 4 cm, those on mechanical ventilation, or those who refused to participate were excluded. The primary outcome was the relationship between changes in renal rSO2 during TAVI and post-procedural AKI. AKI was determined according to the Valve Academic Research Consortium-2 criteria.

Results

Sixty-four patients were included and analyzed. The mean (standard deviation [SD]) age of patients was 82 (4) years, and the median [interquartile range] procedure time was 75 [65–90] min. The incidence of post-procedural AKI was 33% (21/64). There was no difference in the mean (SD) time-weighted renal rSO2 (70% [13%] and 73% [11%]), changes in renal rSO2 (–14% [10%] and − 15% [13%]), or nadir rSO2 (55% [17%] and 60% [17%]) during TAVI between patients who developed post-TAVI AKI and those who did not (p = 0.227, 0.157, and 0.333, respectively). In multivariable regression analysis, renal rSO2 variables were not predictors of post-TAVI AKI.

Conclusion

Procedural changes in renal rSO2 measured using near-infrared spectroscopy did not predict the development of post-TAVI AKI. Further studies are needed to investigate more effective strategies to predict and prevent AKI following TAVI.

Trial registration

This study was registered on cinicaltrials.gov (identifier, NCT04921475, registered on June 10, 2021).